

*Press release*

*20 March 2019*

OnDosis has been chosen as one of the companies selected to the Swedish IVA 100 list (<https://www.iva.se/projekt/research2business/100listan/>). The IVA (Royal Swedish Academy of Engineering Sciences) is an independent academy whose mission is “...to promote the engineering and economic sciences and the advancement of business and industry for the benefit of society”. IVA’s list brings together research that can form the basis of innovation in the form of new companies, new products and services, business development or other form of benefit.

This year, the theme is digitalization. OnDosis has been one of those chosen within the category of Smart Industry.

#### About OnDosis

Swedish life science company OnDosis has developed a proprietary technology to deliver flexible and individualised dosing of oral medicines. By integrating medicines with intelligent dosing and digital capabilities in a handheld device, OnDosis offers a new way to take oral medicines – in micro units. Individualised, intuitive and connected. Initial focus areas are pain, ADHD and immunosuppression. OnDosis is a spin-out from AstraZeneca and headquartered in Gothenburg, Sweden. More information at [www.ondosis.com](http://www.ondosis.com)

Follow us on: [LinkedIn](#)

#### Postal address

OnDosis AB, Erik Dahlbergsgatan 11 A  
41126 Göteborg, Sweden

#### Visiting address

OnDosis AB, AstraZeneca BioVentureHub  
Pepparedsleden 1, 431 50 Mölndal, Sweden